J. Turina, MD; O.M. Hess, MD; M. Turina, MD; H.P. Krayenbuehl, MD T he first successful heart valve replacements were carried out in 1960 with the use of mechanical prostheses.1-3 Because of the risk of thromboembolism that is inherent to all mechanical prostheses and the hazards of continuous anticoagulation, fewer thrombogenic tissue valves were developed. 4, 5 In the early 1960s, homograft replacement of the aortic valve was reported,6'7 and shortly thereafter, valve replacements with porcine bioprostheses were used.8 '9 The adequate hemodynamic properties, low thrombogenicity, and freedom from substantial structural degeneration during the first years after implantation made the bioprostheses a very attractive alternative to mechanical valves. [10] [11] [12] The absence of the need for anticoagulation appeared to be of particular advantage for valve replacement in patients engaged in competitive sports, women wishing to become pregnant, and elderly patients, in whom bleeding complications are most likely to occur. A true consensus about the indications for bioprosthetic valve replacement was, however, never reached in the debate between enthusiastic supporters of tissue valves and skeptical surgeons who were concerned about the long-term durability of the bioprostheses. Nevertheless, bioprostheses were implanted with increasing frequency from the 1970s until the early 1980s, and they were the standard valve substitutes for aortic, mitral, and tricuspid valves in many institutions. After the mid 1980s, the use of bioprostheses decreased due to growing concern about long-term durability of these valves. In the United Kingdom, 1984 was the peak year for use of tissue valve implants; almost 50% of all cardiac valve replacements were with bioprostheses. Over the next 5 years, use of bioprostheses decreased to less than one third of the total. 13 
Types of Bioprostheses
During the past two decades, the largest experience with prosthetic valve replacement has been with the glutaraldehyde-fixed, frame-mounted Hancock and Carpentier-Edwards porcine valves. Over time, modifications of valve design have been accomplished in both prostheses. In 1976, the Hancock modified orifice bioprosthesis was developed to improve hemodynamic performance in the small aortic root.14 This prosthesis features a composite design that removes one coronary cusp and its flow-impeding muscle shelf and replaces it with a cusp from a second larger valve. The probability of freedom from structural valve dysfunction and reoperation at 10 years is similar to that of the Hancock standard valve.14 Similarly, in the early 1980s, the Carpentier-Edwards supra-annular prosthesis was developed to improve hemodynamic properties and durability of the valve. However, the long-term performance of the supra-annular type was 
Bioprostheses Versus Mechanical Valves Information From Observational Studies
The weakness of bioprostheses is their limited durability, and the weaknesses of mechanical valves are their enhanced thrombogenicity and the hazards of chronic anticoagulation.32-37 Durability of bioprostheses is crucially dependent on the site and duration of implantation as well as on the age of the patient.24,27-29.37-40 In observational studies with follow-up of 10 or more years,27-29'37-40 freedom from primary tissue failure in the same age group is approximately 5% to 10% higher for aortic than for mitral valve replacement at 10 years and is even 10% to 20% higher at 12 to 13 years. 38 Thus, longevity of mitral bioprostheses appears to be less than that of aortic ones, probably due to exposure to more pressure and stress when the valve is closed.41'42 Nonperpendicular flow over a mitral prosthesis during systole may be an additional factor contributing to the increased rate of tissue degeneration. Because wear and tear on the atrioventricular valve resulting from systolic pressure rise are lower in the right than in the left ventricle, the longevity of tricuspid bioprostheses is better than that of mitral bioprosthetic implants.43 '44 Bioprosthetic valve failure not only is a function of the site and time after implantation but also is crucially dependent on the age of the patient.24'28'38 '39 Whereas in a 30-year-old patient freedom from valve reoperation is about 40% at 10 years, the incidence of valve failure in those more than 70 years old is low with freedom from reoperation of about 90% for nants of reduced longevity of bioprostheses are diabetes, renal disease, and hypercalcemia.
Increased thrombogenicity and bleeding complications from anticoagulant treatment are the main drawbacks of implantation of mechanical valves. However, in patients with bioprostheses, thromboembolic events also occur, as do hemorrhages, because long-term anticoagulation is used in 8% to 16% of patients with bioprostheses in the aortic position and in 31% to 79% of those with a bioprosthesis in the mitral position.45 A history of embolization, atrial fibrillation, massive left atrial enlargement, and heart failure consequent to impaired left ventricular function are the main reasons for the use of long-term anticoagulation in patients with bioprostheses.
Recently, Grunkemeier and Rahimtoola45 analyzed data regarding thromboembolism, valve thrombosis, and bleeding complications from a number of well-done observational studies with reasonably complete statistics for patients with Starr, Bjork-Shiley, St Jude, and Medtronic-Hall mechanical prostheses or with Hancock and Carpentier-Edwards bioprostheses. In both the aortic and the mitral series, the average weighted risk for thromboembolism did not differ for the mechanical valves and the bioprostheses, although the absolute risk was higher in the mitral (2% to 3.5% thromboembolic events per year) than in the aortic position (1% to 2% thromboembolic events per year) (Fig 1) . There was more variation within the series using a particular valve than among mean values for different valves. Thus, it appears that factors other than valve type have an important impact on the risk of thromboembolism. With respect to valve thrombosis, however, there were distinct differences between mechanical valves and bioprostheses (Fig 2) . In the aortic position, valve thrombotic events ranged from 0.05% (Medtronic-Hall) to 0.25% per year (Bjork-Shiley) for mechanical prostheses, whereas it was less than 0.03% per year for bioprostheses. Similarly, in the mitral position, valve thrombosis rates for mechanical valves (except for Medtronic-Hall) clearly exceeded those of Hancock and CarpentierEdwards bioprostheses. Bleeding complications occurred at the known rate of 1% to 2% per year for continuous anticoagulation in the patients with mechanical valves, whereas they ranged between 0.1% and 0.3% per year for the patients with bioprostheses in the aortic position and between 0.6% and 0.7% per year for patients with bioprostheses in the mitral position.
In summary, it is evident from the numerous observational studies that bioprostheses increasingly result in valve failure due to structural degeneration 7 years after implantation and that valve thrombosis and bleeding complications, but not thromboembolisms, are less frequent in patients with bioprostheses than in those with mechanical valves. hemorrhage is less of an argument against the use of mechanical prostheses today.
Information From Randomized Studies
An important argument against the use of bioprostheses is the unpredictability of the primary tissue failure: in some patients, the valve will fail early, during the first 5 to 10 years, with accompanying major disappointment and loss of trust on the part of the patient. Finally, tissue failure in a patient with a bioprosthesis is not always insidious but can assume proportions of a true clinical emergency, with all of the inherent risks of urgent operation, pulmonary edema, prolonged intubation, and sepsis. In some of these patients, the urgency of the clinical situation does not even allow a proper preoperative evaluation (eg, coronary angiography) because the patient has to be taken to the operating room as soon as possible. 53 Indications for Bioprosthetic Valve Replacement At the present time, there are only a few generally accepted indications for bioprosthesis implantation. These are patients with contraindications to continuous anticoagulation (eg, bleeding disorders, Osler's disease, intestinal polyposis, angiodysplasia) and those in whom the prothrombin time cannot be adequately regulated (eg, compliance problems due to alcoholism, impaired mental function, or drug abuse; health service problems such as that in some Third World countries). A possible indication for bioprosthesis is the patient more than 70 years old who needs aortic valve replacement. In this age group, the occurrence of structural valve degeneration is in general slower and survival is more dependent on non-valve-related complications.54 Thus, the elderly aortic valve patient whose survival is limited can expect to enjoy the remaining years without reoperation and complications arising from long-term anticoagulation. About 40% to 50% of these patients survive operation for 10 and more years. The number of patients with severe primary tissue failure will not be negligible after 10 years, even in this age group. Reop 
